ALPHA DIAGNOSTIC INTERNATIONAL

LIFE TECH Life Technologies™ Your Molecular & Cell Technology Partner

Varicella Zoster Virus Vaccines (VZV) Antibody ELISA Kits, Recombinant Proteins, and Antibodies



Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans and other vertebrates. It commonly causes **chicken-pox in children** and adults and **herpes zoster (shingles) in adults** and rarely in children. As with the other herpes viruses, VZV causes both acute illness and lifelong latency. Before vaccination became widespread, acute primary infection (varicella or "chickenpox") was common during childhood--especially in temperate climates. Zoster typically presents as a painful, localized cutaneous eruption occurring along 1 or more contiguous dermatomes. As with varicella, zoster usually is self-limited in the immunocompetent host, but immunocompromised persons are at risk of more severe illness with cutaneous or visceral dissemination.



Humans are the only known natural hosts of VZV. Transmission of VZV occurs through direct contact with infectious lesions or by inoculation of aerosolized infected droplets onto a susceptible mucosal surface. The virus is transmitted easily; the rate of secondary cases of varicella in susceptible household contacts typically exceeds 90%. Infectivity usually begins 1-2 days before the onset of rash, and patients remain infectious until all vesicular lesions are dried and crusted. In the immunocompetent host, the period of infectiousness is usually 5-7 days after the lesions first appear.In immunocompromised patients, however, healing can be slow and patients may remain infectious for up to several weeks. (25-34). Within the human body it can be treated by a number of drugs and therapeutic agents including acyclovir for the chicken pox, famciclovir, valaciclovir for the shingles, zoster-immune globulin (ZIG), and vidarabine. VZV immune globulin is also a treatment.



Structure of the varicella-zoster virus particle

Expert Reviews in Molecular Medicine ©2005 Cambridge University Press

VZV Vaccines: A live attenuated VZV Oka/Merck strain vaccine is available and is marketed as **Varivax** for the prevention of shingles. **Zostavax** is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age.

Varicella-zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and **human herpes virus type 3 (HHV-3).** VZV is closely related to the herpes simplex viruses (HSV), sharing much genome homology. The known envelope glycoproteins (**gB, gC, gE, gH, gI, gK, gL**) correspond with those in HSV; however, there is no equivalent of HSV gD. The genome is a linear duplex DNA (124 kb). The ELISA test detects VZV-specific IgM antibody in blood; this appears only during chickenpox or herpes zoster and not while the virus is dormant.

About ADI's VZ Vaccine ELISA- ADI has developed antibody ELISA kits to determine the efficacy of VZV vaccines or test new vaccines. The kits can also be used to assess the immune status of humans or animals. Antibody ELISA kits for species or subtypes not listed here can also be provided. Recombinant VZV antigens and antibodies are also available.

Varicella Zoster Virus vaccine Related ELISA kits

(See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2751

ELISA Kit Description	Species	IgG Specific Cat#	IgM Specific Cat#	IgA Specific Cat#
Varicella Zoster Virus (**VZV) Vaccine** Antibody (chickenpox) ELISA Kits	Human	520-200-HVG	520-210-HVM	520-220-HVA
	Mouse	520-230-HVG	520-240-HVM	520-250-MVA
	Monkey	520-260-BVG	520-270-BVM	520-280-VVA

Catalog#	Product Description	Product Type
520-200-01N	Human Anti-VZV IgG negative control serum/plasma (	Serum Controls
520-200-20M	Human Anti-VZV IgG low positive controlserum/plasma (10-30 u/ml)	Serum Controls
520-200-30H	Human Anti-VZV IgG high positive control serum/plasma (>150 u/ml)	Serum Controls
RP-1453	Recomb. (E. Coli) VZV gE (immunnodominant regions 48-153 aa) protein/antigen	Pure protein
RP-1454	Recomb. (E. Coli) VZV ORF9 (immunodominant regions, 6-28, 76-100 aa) protein/antigen	Pure protein
RP-1455	Recomb. (E. Coli) VZV ORF26 (immunnodominant regions 9-33, 184-208aa) protein/antigen	Pure protein
VZV11-M	Monoclonal VZV antigens IgG (pan, recognizes several VZV proteins)	Antibodies
VZV12-M	Monoclonal Varicella Zoster Virus (VZV/chickenpox) nucleocapsid (155 kda protein) IgG	Antibodies
VZV13-M	Monoclonal Varicella Zoster Virus (VZV/chickenpox) early gene 62 (175 kda) protein) IgG	Antibodies
VZV14-M	Monoclonal Varicella Zoster Virus gp1/IV (VZV/chickenpox) glycoprotein I/IV protein) IgG	Antibodies
VZV15-N-500	Varicella Zoster Virus (VZV/chickenpox) antigens/proteins (VZ-10/MRC-5 cells)	Antigens/proteins
VZV16-N-500	Varicella Zoster Virus (VZV/chickenpox) antigens/proteins (Ellen/HF cells)	Antigens/proteins

Varicella_Zoster_Vaccine_Flr Rev. 160614A

India Contact:
Life Technologies (India) Pvt. Ltd.
306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444
Email: customerservice@lifetechindia.com Website: www.lifetechindia.com